YONKERS, N.Y.--(BUSINESS WIRE)--May 12, 2006--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) announced today that it has completed enrollment of subjects in the first part of the Phase I study in Type 2 diabetic patients. In this study, 30 subjects with type 2 diabetes, being treated with sulfonylureas and/or metformin, were expected to be enrolled. The primary objective was to explore the effect of daily doses 4.0 ml of AVR118 given subcutaneously on blood glucose, as compared to subjects not receiving AVR118. All 30 subjects have been enrolled.
